Howard D Palefsky

Bio

Mr. Palefsky has 40 years of experience as an entrepreneur, manager and investor in the medical device and pharmaceutical industries. Mr. Palefsky has been a Managing Director/General Partner/Managing Member of Montreux since 2002 and was a Venture Partner of Montreux from 1999 to 2002. Immediately prior to joining Montreux as a General Partner, Mr. Palefsky was the Chairman and Chief Executive Officer of a Montreux portfolio company, NeurogesX. Mr. Palefsky was the Chairman, President, Chief Executive Officer, and/or Director of Collagen from 1978 to 1997. Collagen was a developer, manufacturer and marketer of medical devices for the treatment of defective, diseased, traumatized or aging tissues. It was sold to Inamed in 1999. Collagen and its affiliated companies made a number of venture capital investments during Mr. Palefsky’s tenure. In addition to his responsibilities as CEO, Mr. Palefsky was directly responsible for these investments and, in each case, served as Collagen’s representative on the board of directors. In addition to his activities at Collagen, Mr. Palefsky has been active in the medical device and pharmaceutical industries during his entire career. His activities have included serving on the boards of numerous public and private companies, providing advice and guidance to companies, entrepreneurs and managers with regard to industry trends, strategy and making private investments. Mr. Palefsky received his M.B.A. in 1971 from the Stanford University Graduate School of Business and his B.S. from the City College of the City University of New York in 1967. Mr. Palefsky served as an officer in the United States Public Health Service from 1967 to 1969 and was honorably discharged with the rank of Lt (jg). Mr. Palefsky was a member of the Young President’s Organization from 1984 to 1997 and is currently a member of the World President’s Organization and The Chief Executives Organization. Mr. Palefsky currently is a member of the board of directors of four Montreux portfolio companies: Avantis, PulmonX, NovoStent, PercSys and GC Aesthetics. He is also actively involved in managing Montreux’s investment in Asthmatx. He previously served on the board of directors of Questcor (AMEX: QSC), Coalescent (sold to Medtronic, 2004), Enteric (sold to Boston Scientific, 2002), and Pro-Duct (sold to Cytyc, 2002).